Journal of Clinical Pediatrics >
Application of biological agents in idiopathic nephrotic syndrome
Received date: 2021-10-15
Online published: 2022-10-12
Idiopathic nephrotic syndrome (INS) is the commonest glomerular disease in children. Refractory nephrotic syndromes such as frequent relapses, steroid dependence and steroid resistance are still the current difficulties in clinical INS treatment. In recent years, it has been reported that rituximab (RTX) and other biological agents have been used in the treatment of refractory nephrotic syndrome and have achieved good results. This article reviews the application progress of RTX and other biological agents in INS.
Key words： nephrotic syndrome; biological agent; rituximab; child
Qianhui Reviewer: WANG , Fei LIU , Haidong FU , Jianhua Reviser: MAO . Application of biological agents in idiopathic nephrotic syndrome[J]. Journal of Clinical Pediatrics, 2022 , 40(10) : 787 -794 . DOI: 10.12372/jcp.2022.21e1440
| [1] | Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children[J]. Lancet, 2018, 392(10141): 61-74. |
| [2] | Chen J, Qiao XH, Mao JH. Immunopathogenesis of idiopathic nephrotic syndrome in children: two sides of the coin[J]. World J Pediatr, 2021, 17(2): 115-122. |
| [3] | Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases[J]. Kidney Int, 2021, 100(4): 753-779. |
| [4] | Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome[J]. Pediatr Nephrol, 2020, 35(8): 1529-1561. |
| [5] | Wei C, Trachtman H, Li J, et al. Circulating suPAR in two cohorts of primary FSGS[J]. J Am Soc Nephrol, 2012, 23(12): 2051-2059. |
| [6] | Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis[J]. Sci Transl Med, 2011, 3(85): 85ra46. |
| [7] | Benz K, Dötsch J, Rascher W, et al. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy[J]. Pediatr Nephrol, 2004, 19(7): 794-797. |
| [8] | Boumediene A, Vachin P, Sendeyo K, et al. NEPHRUTIX: a randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in minimal change nephrotic syndrome[J]. J Autoimmun, 2018, 88: 91-102. |
| [9] | Iwabuchi Y, Miyabe Y, Makabe S, et al. Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease[J]. Medicine (Baltimore), 2018, 97(42): e12704. |
| [10] | Hogan J, Deschenes G. How to improve response to rituximab treatment in children with steroid-dependent nephrotic syndrome: answer to Drs. Fujinaga and Nishino[J]. Pediatr Nephrol, 2019, 34(2): 361-362. |
| [11] | Maxted AP, Dalrymple RA, Chisholm D, et al. Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome[J]. Pediatr Nephrol, 2019, 34(5): 855-863. |
| [12] | Ravani P, Magnasco A, Edefonti A, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial[J]. Clin J Am Soc Nephrol, 2011, 6(6): 1308-1315. |
| [13] | Iijima K, Sako M, Nozu K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial[J]. Lancet, 2014, 384(9950): 1273-1281. |
| [14] | Ahn YH, Kim SH, Han KH, et al. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea[J]. Medicine (Baltimore), 2018, 97(46): e13157. |
| [15] | Basu B, Sander A, Roy B, et al. Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial[J]. JAMA Pediatr, 2018, 172(8): 757-764. |
| [16] | Ravani P, Lugani F, Drovandi S, et al. Rituximab vs low-dose mycophenolate mofetil in recurrence of steroid-dependent nephrotic syndrome in children and young adults: a randomized clinical trial[J]. JAMA Pediatr, 2021, 175(6): 631-632. |
| [17] | Kim JH, Park E, Hyun HS, et al. Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome[J]. Kidney Res Clin Pract, 2017, 36(3): 257-263. |
| [18] | Gulati A, Sinha A, Jordan SC, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report[J]. Clin J Am Soc Nephrol, 2010, 5(12): 2207-2212. |
| [19] | Magnasco A, Ravani P, Edefonti A, et al. Rituximab in children with resistant idiopathic nephrotic syndrome[J]. J Am Soc Nephrol, 2012, 23(6): 1117-1124. |
| [20] | Hoseini R, Sabzian K, Otukesh H, et al. Efficacy and safety of rituximab in children with steroid- and cyclosporine-resistant and steroid- and cyclosporine-dependent nephrotic syndrome[J]. Iran J Kidney Dis, 2018, 12(1): 27-32. |
| [21] | Nakagawa T, Shiratori A, Kawaba Y, et al. Efficacy of rituximab therapy against intractable steroid-resistant nephrotic syndrome[J]. Pediatr Int, 2016, 58(10): 1003-1008. |
| [22] | Zachwieja J, Silska-Dittmar M, Żurowska A, et al. Multicenter analysis of the efficacy and safety of a non-standard immunosuppressive therapy with rituximab in children with steroid-resistant nephrotic syndrome[J]. Clin Exp Pharmacol Physiol, 2019, 46(4): 313-321. |
| [23] | Kamei K, Okada M, Sato M, et al. Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome[J]. Pediatr Nephrol, 2014, 29(7): 1181-1187. |
| [24] | Fujinaga S, Nishino T, Umeda C, et al. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome[J]. Pediatr Nephrol, 2019, 34(2): 353-357. |
| [25] | Ruggenenti P, Ruggiero B, Cravedi P, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome[J]. J Am Soc Nephrol, 2014, 25(4): 850-863. |
| [26] | Delbet JD, Leclerc G, Ulinski T. Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery?[J]. Pediatr Nephrol, 2019, 34(3): 529-532. |
| [27] | Kamei K, Ogura M, Sato M, et al. Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome[J]. Pediatr Nephrol, 2018, 33(6): 1013-1018. |
| [28] | Kamei K, Takahashi M, Fuyama M, et al. Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature[J]. Nephrol Dial Transplant, 2015, 30(1): 91-96. |
| [29] | Ardelean DS, Gonska T, Wires S, et al. Severe ulcerative colitis after rituximab therapy[J]. Pediatrics, 2010, 126(1): e243-e246. |
| [30] | Sellier-Leclerc AL, Belli E, Guérin V, et al. Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome[J]. Pediatr Nephrol, 2013, 28(9): 1875-1879. |
| [31] | Boren EJ, Cheema GS, Naguwa SM, et al. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases[J]. J Autoimmun, 2008, 30(1-2): 90-98. |
| [32] | Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab[J]. Expert Opin Drug Saf, 2005, 4(3): 599-608. |
| [33] | Basu B. Ofatumumab for rituximab-resistant nephrotic syndrome[J]. N Engl J Med, 2014, 370(13): 1268-1270. |
| [34] | Bonanni A, Rossi R, Murtas C, et al. Low-dose ofatu-mumab for rituximab-resistant nephrotic syndrome[J]. BMJ Case Rep, 2015, 2015: bcr2015210208. |
| [35] | Vivarelli M, Colucci M, Bonanni A, et al. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab[J]. Pediatr Nephrol, 2017, 32(1): 181-184. |
| [36] | Wang CS, Liverman RS, Garro R, et al. Ofatumumab for the treatment of childhood nephrotic syndrome[J]. Pediatr Nephrol, 2017, 32(5): 835-841. |
| [37] | Ravani P, Pisani I, Bodria M, et al. Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial[J]. Pediatr Nephrol, 2020, 35(6): 997-1003. |
| [38] | Ravani P, Colucci M, Bruschi M, et al. Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial[J]. J Am Soc Nephrol, 2021, 32(10): 2652-2663. |
| [39] | Bonanni A, Calatroni M, D'Alessandro M, et al. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome[J]. Br J Clin Pharmacol, 2018, 84(6): 1238-1249. |
| [40] | Alachkar N, Carter-Monroe N, Reiser J. Abatacept in B7-1-positive -positive proteinuric kidney disease[J]. N Engl J Med, 2014, 370(13): 1263-1264. |
| [41] | Garin EH, Diaz LN, Mu W, et al. Urinary CD80 excretion increases in idiopathic minimal-change disease[J]. J Am Soc Nephrol, 2009, 20(2): 260-266. |
| [42] | Salant DJ. Podocyte expression of B7-1/CD80: is it a reliable biomarker for the treatment of proteinuric kidney diseases with abatacept?[J]. J Am Soc Nephrol, 2016, 27(4): 963-965. |
| [43] | Kaneko K, Tsuji S, Kimata T, et al. Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes[J]. World J Pediatr, 2015, 11(1): 21-28. |
| [44] | Chen P, Chen Y, Jiang M, et al. Usefulness of the cytokines expression of Th1/Th2/Th17 and urinary CD80 excretion in adult-onset minimal change disease[J]. Peer J, 2020, 8: e9854. |
| [45] | Szeto CC, Lai FM, Chow KM, et al. Long-term outcome of biopsy-proven minimal change nephropathy in Chinese adults[J]. Am J Kidney Dis, 2015, 65(5): 710-718. |
| [46] | Grellier J, Del Bello A, Milongo D, et al. Belatacept in recurrent focal segmental glomerulosclerosis after kidney transplantation[J]. Transpl Int, 2015, 28(9): 1109-1110. |
| [47] | Novelli R, Gagliardini E, Ruggiero B, et al. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?[J]. Am J Physiol Renal Physiol, 2016, 310(5): F335-341. |
| [48] | Hansrivijit P, Puthenpura MM, Ghahramani N. Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: a systematic review of case reports, case series, and observational studies[J]. Clin Nephrol, 2020, 94(3): 117-126. |
| [49] | Trachtman H, Gipson DS, Somers M, et al. Randomized clinical trial design to assess abatacept in resistant nephrotic syndrome[J]. Kidney Int Rep, 2018, 3(1): 115-121. |
| [50] | Mishra OP, Kumar R, Narayan G, et al. Toll-like receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome[J]. Pediatr Nephrol, 2017, 32(8): 1355-1361. |
| [51] | Trachtman H, Fervenza FC, Gipson DS, et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis[J]. Kidney Int, 2011, 79(11): 1236-1243. |
| [52] | Vincenti F, Fervenza FC, Campbell KN, et al. A phase 2, double-blind, placebo-controlled, randomized study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis[J]. Kidney Int Rep, 2017, 2(5): 800-810. |
| [53] | Joy MS, Gipson DS, Powell L, et al. Phase 1 trial of adalimumab in focal segmental glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group[J]. Am J Kidney Dis, 2010, 55(1): 50-60. |
| [54] | Trachtman H, Vento S, Herreshoff E, et al. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group[J]. BMC Nephrol, 2015, 16: 111. |
| [55] | Schmidt T, Schulze M, Harendza S, et al. Successful treatment of PLA2R1-antibody positive membranous nephropathy with ocrelizumab[J]. J Nephrol, 2021, 34(2): 603-606. |
| [56] | Wolinsky JS, Arnold DL, Brochet B, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial[J]. Lancet Neurol, 2020, 19(12): 998-1009. |
| [57] | Ayrignac X, Bilodeau PA, Prat A, et al. Assessing the risk of multiple sclerosis disease-modifying therapies[J]. Expert Rev Neurother, 2019, 19(7): 695-706. |
| [58] | Le Quintrec M, Lapeyraque AL, Lionet A, et al. Patterns of clinical response to eculizumab in patients with C3 glomerulopathy[J]. Am J Kidney Dis, 2018, 72(1): 84-92. |
| [59] | Ruggenenti P, Daina E, Gennarini A, et al. C5 convertase blockade in membranoproliferative glomerulonephritis: a single-arm clinical trial[J]. Am J Kidney Dis, 2019, 74(2): 224-238. |
/
| 〈 |
|
〉 |
